Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of adult acute myelogenous leukemia in first complete remission

Leukemia volume 17, pages 2183–2188 (2003)Cite this article

Abstract

In order to improve leukemia-free survival (LFS) without the treatment-related morbidity of allogeneic bone marrow transplantation or multiple prolonged cycles of consolidation chemotherapy, we evaluated the long-term outcome of autologous transplantation of peripheral blood progenitor cells (PBPCs) as postremission therapy in 129 patients aged 18–71 years (median 49 years) with newly diagnosed acute myelogenous leukemia (AML) in first complete remission (CR1). The median follow-up from remission for surviving patients was 62.2 months (range 3.7–127.9 months). A total of 57 patients were alive and leukemia free at the end of the study. The LFS and overall survival 5 years from remission were 40.2% (±9.2%) and 41.4% (±9.4%), respectively. The median LFS and overall survival are 17.3 and 23.3 months, respectively. Multivariate analysis identified age as the most significant predictor for both LFS and overall survival. Karyotype was also found to be predictive of outcome. Our results show that autologous transplantation of PBPC procured after a single cycle of high-dose cytarabine-based consolidation chemotherapy for a population of adult patients with AML in CR1 produces a high likelihood of long-term LFS, offering a state of clinical minimal residual disease for the investigation of future therapeutic approaches.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Cassileth PA, Begg CB, Bennett JM, Bozdech M, Kahn SB, Weiler C et al. A randomized study of the efficacy of consolidation therapy in adult acute nonlymphocytic leukemia. Blood 1984; 63: 843–847.

    CAS  PubMed  Google Scholar 

  2. Preisler HD, Raza A, Early A, Kirshner J, Brecher M, Freeman A et al. Intensive remission consolidation therapy in the treatment of acute nonlymphocytic leukemia. J Clin Oncol 1987; 5: 722–730.

    Article  CAS  Google Scholar 

  3. Phillips GL, Shepherd JD, Barnett MJ, Brown RA, Frei-Lahr DA, Klingemann HG et al. High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 1991; 77: 1429–1435.

    CAS  PubMed  Google Scholar 

  4. Appelbaum FR, Dahlberg S, Thomas ED, Buckner CD, Cheever MA, Clift RA et al. Bone marrow transplantation or chemotherapy after remission induction for adults with acute nonlymphoblastic leukemia. A prospective comparison. Ann Intern Med 1984; 101: 581–588.

    Article  CAS  Google Scholar 

  5. Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994; 331: 896–903.

    Article  CAS  Google Scholar 

  6. Schiffer CA, Dodge R, Larson RA . Long-term follow-up of Cancer and Leukemia Group B studies in acute myeloid leukemia. Cancer 1997; 80 (Suppl.): 2210–2214.

    Article  CAS  Google Scholar 

  7. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 1995; 86: 2041–2050.

    CAS  Google Scholar 

  8. Berman E, Little C, Gee T, O'Reilly R, Clarkson B . Reasons that patients with acute myelogenous leukemia do not undergo allogeneic bone marrow transplantation. N Engl J Med 1992; 326: 156–160.

    Article  CAS  Google Scholar 

  9. Lowenberg B, Verdonck LJ, Dekker AW, Willemze R, Zwaan FE, de Planque M et al. Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study. J Clin Oncol 1990; 8: 287–294.

    Article  CAS  Google Scholar 

  10. Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P et al. Granulocyte–macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B. N Engl J Med 1995; 332: 1671–1677.

    Article  CAS  Google Scholar 

  11. Laporte JP, Douay L, Lopez M, Labopin M, Jouet JP, Lesage S et al. One hundred twenty-five adult patients with primary acute leukemia autografted with marrow purged by mafosfamide: a 10-year single institution experience. Blood 1994; 84: 3810–3818.

    CAS  Google Scholar 

  12. Mehta J, Powles R, Singhal S, Horton C, Tait D, Milan S et al. Autologous bone marrow transplantation for acute myeloid leukemia in first remission: identification of modifiable prognostic factors. Bone Marrow Transplant 1995; 16: 499–506.

    CAS  PubMed  Google Scholar 

  13. Bensinger WI, Deeg HJ . Blood or marrow? Lancet 2000; 355: 1199–1200.

    Article  CAS  Google Scholar 

  14. Stein AS, Chai A, Schmidt GM, Nademanee A, Parker PM, Smith EP et al. In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission. J Clin Oncol 1996; 14: 2206–2216.

    Article  CAS  Google Scholar 

  15. Reiffers J, Labopin M, Sanz M, Korbling M, Blaise D, De La Rubia J et al. Autologous blood cell vs marrow transplantation for acute myeloid leukemia in complete remission: an EBMT retrospective analysis. Bone Marrow Transplant 2000; 25: 1115–1119.

    Article  CAS  Google Scholar 

  16. Bennett JM, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C . Proposals for the classification of acute leukaemias. French–American–British (FAB) co-operative group. Br J Haematol 1977; 33: 451–458.

    Article  Google Scholar 

  17. Schiller G, Territo M, Nimer S, Lee M, Belin T, Champlin R . Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia. Blood 1992; 80: 2977–2982.

    CAS  PubMed  Google Scholar 

  18. Schiller GJ, Nimer SD, Territo MC, Ho WG, Champlin RE, Gajewski JL . Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission. J Clin Oncol 1992; 10: 41–46.

    Article  CAS  Google Scholar 

  19. Ellison RR, Holland JF, Weil M, Jacquillat C, Boiron M, Bernard J et al. Arabinosyl cytosine: a useful agent in the treatment of acute leukemia in adults. Blood 1968; 32: 507–523.

    CAS  PubMed  Google Scholar 

  20. Schiller G, Wong S, Lowe T, Snead G, Paquette R, Sawyers C et al. Transplantation of IL-2-mobilized autologous peripheral blood progenitor cells for adults with acute myelogenous leukemia in first remission. Leukemia 2001; 15: 757–763.

    Article  CAS  Google Scholar 

  21. Sun GX, Gale RP, Sparkes RS, Schreck RR . Use of conditioned media in cell culture can mask cytogenetic abnormalities in acute leukemia. Cancer Genet Cytogenet 1990; 46: 107–113.

    Article  CAS  Google Scholar 

  22. Dinse GE, Lagakos SW . Nonparametric estimation of lifetime and disease onset distributions from incomplete observations. Biometrics 1982; 38: 921–932.

    Article  CAS  Google Scholar 

  23. Allison P . Survival Analysis Using the SAS System: A Practical Guide. Cary, NC, 1998, SAS Publishing.

    Google Scholar 

  24. Schiffer CA . Acute myeloid leukemia in adults: where do we go from here? Cancer Chemother Pharmacol 2001; 48: S45–S52.

    Article  Google Scholar 

  25. Hiddemann W . Treatment strategies in acute myeloid leukemia (AML). B. Second line treatment. Blut 1990; 60: 163–171.

    Article  CAS  Google Scholar 

  26. Wolff SN, Fay JW, Phillips GL, Lazarus HM, Flexner JM, Stein RS et al. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results. J Clin Oncol 1989; 7: 1260–1267.

    Article  CAS  Google Scholar 

  27. Spellberg B, Schiller GL . Autologous bone marrow transplantation in acute leukemia. Hematol Oncol Clin N Am 1999; 13: 919–938.

    Article  CAS  Google Scholar 

  28. Korbling M, Hunstein W, Fliedner TM, Cayeux S, Dorken B, Fehrentz D et al. Disease-free survival after autologous bone marrow transplantation in patients with acute myelogenous leukemia. Blood 1989; 74: 1898–1904.

    CAS  PubMed  Google Scholar 

  29. Zittoun RA, Mandelli F, Willemze R, de Witte T, Labar B, Resegotti L et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995; 332: 217–223.

    Article  CAS  Google Scholar 

  30. Harousseau JL, Cahn JY, Pignon B, Witz F, Milpied N, Delain M et al. Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM). Blood 1997; 90: 2978–2986.

    CAS  Google Scholar 

  31. Burnett AK, Goldstone AH, Stevens RM, Hann IM, Rees JK, Gray RG et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998; 351: 700–708.

    Article  CAS  Google Scholar 

  32. Cassileth PA, Harrington DP, Appelbaum FR, Lazarus HM, Rowe JM, Paietta E et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998; 339: 1649–1656.

    Article  CAS  Google Scholar 

  33. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075–4083.

    CAS  PubMed  Google Scholar 

  34. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH et al. The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002; 118: 385–400.

    Article  Google Scholar 

  35. Frassoni F . Randomised studies in acute myeloid leukaemia: the double truth. Bone Marrow Transplant 2000; 25: 471–473.

    Article  CAS  Google Scholar 

  36. Cahn JY, Labopin M, Schattenberg A, Reiffers J, Willemze R, Zittoun R et al. Allogeneic bone marrow transplantation for acute leukemia in patients over the age of 40 years. Acute Leukemia Working Party of the European Group for Bone Marrow Transplantation (EBMT). Leukemia 1997; 11: 416–419.

    Article  CAS  Google Scholar 

  37. Cahn JY, Labopin M, Mandelli F, Goldstone AH, Eberhardt K, Reiffers J et al. Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years: a retrospective analysis of the European Bone Marrow Transplant Group. Blood 1995; 85: 575–579.

    CAS  PubMed  Google Scholar 

  38. Sekeres MA . The challenge of acute myeloid leukemia in older patients. Curr Opin Oncol 2002; 14: 24–30.

    Article  Google Scholar 

  39. Pinto A, Ferrara F . Acute myeloid leukemia in the elderly: biology and therapeutic strategies. Crit Rev Oncol Hematol 2001; 39: 275–287.

    Article  CAS  Google Scholar 

  40. Wahlin A, Golovleva I, Nilsson M . Prognostic significance of risk group stratification in elderly patients with acute myeloid leukaemia. Br J Haematol 2001; 115: 25–33.

    Article  CAS  Google Scholar 

  41. Linker CA, Damon LE, Ries CA, Navarro WA, Case D, Wolf JL . Autologous stem cell transplantation for advanced acute myeloid leukemia. Bone Marrow Transplant 2002; 29: 297–301.

    Article  CAS  Google Scholar 

  42. Gorin NC . Autologous stem cell transplantation for adult acute leukemia. Curr Opin Oncol 2002; 14: 152–159.

    Article  Google Scholar 

Download references

Acknowledgements

This study was supported in part by the Joseph Troy Leukemia Fund. EAC was supported by USHHS Institutional National Research Service Award T32 CA09056.

Author information

Author notes

  1. E A Collisson

    Present address: Department of Medicine, Stanford University, 300 Pasteur Dr., Palo Alto, CA 94305, USA

Authors and Affiliations

  1. Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA

    E A Collisson, A Lashkari, R Malone, R Paquette, C Emmanouilides, M C Territo & G J Schiller

Authors
  1. E A Collisson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Lashkari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R Malone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Paquette
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C Emmanouilides
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M C Territo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. G J Schiller
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Collisson, E., Lashkari, A., Malone, R. et al. Long-term outcome of autologous transplantation of peripheral blood progenitor cells as postremission management of adult acute myelogenous leukemia in first complete remission. Leukemia 17, 2183–2188 (2003). https://doi.org/10.1038/sj.leu.2403126

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403126

Keywords

This article is cited by

Search

Advanced search

Quick links